参考文献:
1. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
3.Cheng Y,Wang QM,Li K,et al.ANLOTINIB AS THIRD-LINE OR FURTHER-LINE TREATMENT IN RELAPSED SCLC:A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL[EB/OL].WCLC 2018,abstract OA13.03.
4.Wang QM,Cheng Y,Li K,et al.Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial[EB/OL].WCLC 2019,abstract OA03.02.
5.Cheng Y,Wang QM,Li K,et al.The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases:A Subgroup Analysis of ALTER 1202[EB/OL].WCLC 2019,abstract P2.12-26.
声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
本文版权归找药宝典所有,任何个人或机构转载需获得找药宝典授权,在授权范围内使用,并标注来源“找药宝典”。
文章转载、媒体合作请联系小编:p88128812
联系客服